Trisoxireno[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-8b-methyl-6a-(1-methylethyl)-6-[(phosphonooxy)methoxy]-, sodium salt (1:2), (3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)-

Request For Quotation
Trisoxireno[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-8b-methyl-6a-(1-methylethyl)-6-[(phosphonooxy)methoxy]-, sodium salt (1:2), (3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)- Suppliers list
Company Name: TargetMol Chemicals Inc.
Tel: +1-781-999-5354; +17819995354
Email: marketing@targetmol.com
Products Intro: Product Name:Minnelide
CAS:1254702-87-8
Purity:98.00% Package:100 mg；500 mg Remarks:REAGENT;FOR LABORATORY USE ONLY
Company Name: HANGZHOU CLAP TECHNOLOGY CO.,LTD
Tel: 86-571-88216897,88216896 13588875226
Email: sales@hzclap.com
Products Intro: Product Name:Minnelide
CAS:1254702-87-8
Purity:59799% Package:10kg 25kg 200 kilograms per barrel Remarks:good
Company Name: TargetMol Chemicals Inc.
Tel: +1-781-999-5354;
Email: support@targetmol.com
Products Intro: Product Name:Minnelide
CAS:1254702-87-8
Purity:99.59% Package:50mg;|25mg;|100mg;
Company Name: ShangHai Caerulum Pharma Discovery Co., Ltd.  
Tel: 18149758185 18149758185
Email: sales-cpd@caerulumpharma.com
Products Intro: Product Name:Minnelide sodium
CAS:1254702-87-8
Purity:98% Package:1g;10g;100g
Company Name: Shanghai EFE Biological Technology Co., Ltd.  
Tel: 021-65675885 18964387627
Email: info@efebio.com
Products Intro: Product Name:Minnelide
CAS:1254702-87-8
Purity:98.00% Package:2mg;5mg;25mg

Trisoxireno[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-8b-methyl-6a-(1-methylethyl)-6-[(phosphonooxy)methoxy]-, sodium salt (1:2), (3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)- manufacturers

  • Minnelide
  • Minnelide pictures
  • 2026-04-20
  • CAS:1254702-87-8
  • Purity: 99.59%
  • Supply Ability: 10g
Trisoxireno[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-8b-methyl-6a-(1-methylethyl)-6-[(phosphonooxy)methoxy]-, sodium salt (1:2), (3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)- Basic information
Product Name:Trisoxireno[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-8b-methyl-6a-(1-methylethyl)-6-[(phosphonooxy)methoxy]-, sodium salt (1:2), (3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)-
Synonyms:Triptolide Impurity 1;Minnelide sodium;Triheptanoin Impurity 9;Trisoxireno[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-8b-methyl-6a-(1-methylethyl)-6-[(phosphonooxy)methoxy]-, sodium salt (1:2), (3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)-;Minnelide
CAS:1254702-87-8
MF:C21H27O10P.2Na
MW:516.39
EINECS:
Product Categories:
Mol File:1254702-87-8.mol
Trisoxireno[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-8b-methyl-6a-(1-methylethyl)-6-[(phosphonooxy)methoxy]-, sodium salt (1:2), (3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)- Structure
Trisoxireno[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-8b-methyl-6a-(1-methylethyl)-6-[(phosphonooxy)methoxy]-, sodium salt (1:2), (3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)- Chemical Properties
storage temp. Store at -20°C
solubility DMSO (Slightly), Methanol (Slightly)
form Solid
color White
Safety Information
MSDS Information
Trisoxireno[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-8b-methyl-6a-(1-methylethyl)-6-[(phosphonooxy)methoxy]-, sodium salt (1:2), (3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)- Usage And Synthesis
UsesTriptolide (T815600) derivative. Diterpenoid triepoxide with immunosuppressant and antitumor properties.
in vivo

Minnelide (injection intraperitoneally; 0.1-0.6 mg/kg; once daily or twice daily) leads to a marked decrease in tumor weight and volume at the end of treatment and increases survival in orthotopic model of pancreatic cancer with MIA PaCa-2–derived human pancreatic tumors[2]. Minnelide (injection intraperitoneally; 0.42 mg/kg; once daily; 28 days) prevents locoregional spread and leads to a decrease in average tumor weight in a xenograft model of pancreatic cancer with metastatic S2-013 cells[2]. Minnelide (injection intraperitoneally; 0.42 mg/kg, 0.21 mg/kg; once daily) causes tumor regression and tumors from Minnelide-treated animals showed fibrosis and the presence of pyknotic nuclei in human pancreatic cancer xenografts in SCID mice[2].

Animal Model:Orthotopic model of pancreatic cancer with MIA PaCa 2-derived human pancreatic tumors in athymic nude mice[2]
Dosage:0.1-0.6 mg/kg
Administration:Injection intraperitoneally; 0.1-0.6 mg/kg; once daily or twice daily
Result:Prevented pancreatic tumor growth in vivo.
Animal Model:Xenograft model of pancreatic cancer with metastatic S2-013 cell line in athymic nude mice[2]
Dosage:0.42 mg/kg
Administration:Injection intraperitoneally; 0.42 mg/kg; once daily
Result:Prevented extensive spread from the primary site of injection.
Animal Model:Human pancreatic cancer xenografts in SCID mice[2]
Dosage:0.21 mg/kg, 0.42 mg/kg
Administration:Injection intraperitoneally; 0.42 mg/kg; once daily
Result:Reduced tumor burden in human xenografts from patients.
Trisoxireno[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-8b-methyl-6a-(1-methylethyl)-6-[(phosphonooxy)methoxy]-, sodium salt (1:2), (3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)- Preparation Products And Raw materials
Tag:Trisoxireno[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-8b-methyl-6a-(1-methylethyl)-6-[(phosphonooxy)methoxy]-, sodium salt (1:2), (3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)-(1254702-87-8) Related Product Information